Business Context and Reporting Period
Company: MDB Capital Holdings, LLC (MDBH)
Filing Type: Form 8-K (Current Report)
Date of Report: July 8, 2024
Event Date: June 13, 2024
Context: MDB reported the entry into a material definitive contract involving the funding of a new subsidiary, MDB Minnesota One, Inc. ("Minnesota One"), to develop a small molecule senescence platform based on technology licensed from the Mayo Foundation for Medical Education and Research ("Mayo").
Key Financial Metrics and Contract Terms
The filing details specific financial commitments related to the new venture rather than consolidated operating results for MDB Capital Holdings, LLC.
- Up-Front License Fee: $150,000 payable by Minnesota One to Mayo.
- Investment Commitment: MDB may invest up to $5,000,000 into Minnesota One over a 5-year period.
- Investment Structure: Capital injections are tied to business needs and increments.
- Ownership Structure: As of the agreement date, MDB owns 67% and Mayo owns 33% of Minnesota One's common stock.
- Future Obligations: Minnesota One must achieve developmental and funding milestones and pay royalties on net sales of licensed products.
Note: The filing text does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for MDB Capital Holdings, LLC for the reporting period.
Material Changes and Strategic Actions
The primary material change is the formation of a new corporate entity and the execution of two key agreements:
- License Agreement: Minnesota One secured rights to Mayo's patent and know-how for a senescence platform.
- Term Equity Purchase Agreement: MDB established a framework to provide operational capital to Minnesota One in exchange for equity.
Mayo retains a right of participation in future financings of Minnesota One.
Outlook, Management Commentary, and Risks
Management Strategy: MDB intends to develop Minnesota One's business similarly to its approach with other university-licensed technologies. The company plans to rename the entity once the business strategy is fully formulated.
Long-Term Goal: The ultimate objective is to list Minnesota One on a national exchange to facilitate commercialization and funding efforts.
Risks and Contingencies:
- Continued rights under the License Agreement are contingent upon achieving specific developmental and funding milestones within designated time periods.
- Future profitability is dependent on the successful commercialization of the licensed technology and the generation of net sales subject to royalties.
Key Facts for Investor Verification
- Verify the specific developmental and funding milestones required to maintain the License Agreement with Mayo.
- Monitor the actual drawdown of the $5,000,000 investment commitment against the 5-year timeline.
- Track the progress of the "small molecule senescence platform" development.
- Confirm the timeline and criteria for the potential renaming and future listing of Minnesota One on a national exchange.